Please assess the completion status of the following clinical trial:

Trial Title: Continuous Administration of Oral Contraceptive, Primary Dysmenorrhea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy women ages 18-35 with a history of PD (onset \< 3 years after menarche).~* Subjects must have had regular (25-31 day) menstrual cycles for the three month period preceding enrollment, with symptoms of moderate to severe PD during those cycles.~Exclusion Criteria:~* Patients who have contraindications to OCP therapy.~* Known or suspected secondary dysmenorrhea (major abdominal or pelvic surgery, endometriosis, pelvic inflammatory disease (PID), ovarian cysts, pathological vaginal secretion, chronic abdominal pain, inflammatory bowel disease, irritable bowel syndrome).~* Concomitant treatment with oral contraceptives, GnRH agonists and antagonists, antiandrogens, gonadotropins, anti-obesity drugs.~* The use of contraceptive implants, injectable contraceptives or intrauterine devices. The washout period on all these medications will be 3 months.~* Migraines, depression requiring hospitalization or associated with suicidal ideation during previous estrogen or ocp use.~* Known or suspected hypersensitivity to trial drug.~* Patients enrolled simultaneously into other investigative studies that require meds.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- study group (CCOCP) (Type: EXPERIMENTAL): treatment with monophasic oral contraceptive (gestodene 0,075 mg /ethinyl estradiol 20 mcg) for 168 continuous days through six cycles
- control group (traditional OCP) (Type: ACTIVE_COMPARATOR): treatment with monophasic oral contraceptive (gestodene 0,075 mg /ethinyl estradiol 20 mcg) for traditional (21 active days/7 inactive days) regimen through six cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).